Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology

Experimental and Molecular Pathology

Volumn 95, Issue 1, 2013, Pages 74-82

  Perez, K ^a   Walsh, R ^a   Brilliant, K ^a   Noble, L ^a   Yakirevich, E ^a   Breese, V ^a   Jackson, C ^a   Chatterjee, D ^a   Pricolo, V ^a   Roth, L ^a   Shah, N ^a   Cataldo, T ^a   Safran, H ^a   Hixson, D ^a   Quesenberry, P ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Colorectal cancer; KRAS; WAVE system

Indexed keywords

ALLELE; ARTICLE; BIOTECHNOLOGY; CODON; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE MUTATION; GENE SEQUENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KRAS GENE; LABORATORY DEVICE; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

COLORECTAL CANCER; KRAS; WAVE SYSTEM;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84879147359     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.01.004     Document Type: Article

References (19)

1. Bastien P., Procop G.W., Reischl U. Quantitative real-time PCR is not more sensitive than "conventional" PCR. Journal of Clinical Microbiology 2008, 46(6):1897-1900.
2. Chambers P.A., et al. Mutation detection by clonal sequencing of PCR amplicons and grouped read typing is applicable to clinical diagnostics. Human Mutation 2012.
3. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 2012, 366(10):883-892.
4. Harismendy O., et al. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biology 2011, 12(12):R124.
5. Hecht J.R., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27(5):672-680.
6. Janne P.A., et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clinical Cancer Research 2006, 12(3 Pt 1):751-758.
7. Jonker D.J., et al. Cetuximab for the treatment of colorectal cancer. The New England Journal of Medicine 2007, 357(20):2040-2048.
8. Karapetis C.S., et al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008, 359(17):1757-1765.
9. Lamy A., et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Modern Pathology 2011, 24(8):1090-1100.
10. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006, 66(8):3992-3995.
11. Milbury C.A., et al. COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. Clinical Chemistry 2012, 58(3):580-589.
12. Misale S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012, 486(7404):532-536.
13. Normanno N., et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature Reviews. Clinical Oncology 2009, 6(9):519-527.
14. Otsuka K., et al. Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. Oncology Letters 2012, 3(3):649-653.
15. Pandey J.P. Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes. MAbs 2012, 4(5):553-554.
16. Richman S.D., et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Analytical Cellular Pathology (Amsterdam) 2011, 34(1-2):61-66.
17. Saltz L.B., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Journal of Clinical Oncology 2007, 25(29):4557-4561.
18. Tol J., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. The New England Journal of Medicine 2009, 360(6):563-572.
19. van Krieken J.H., et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Archiv 2008, 453(5):417-431.